Good find Hodgie.... old Ai seems to think it's a positive also -
this shift is squarely in Imugene’s favor. By stripping away CMS-mandated registry requirements and loosening reimbursement hurdles for CAR-T therapies, the FDA/CMS combo is making it far easier and cheaper for centers to offer these treatments. That means off-the-shelf programs like Imugene’s azer-cel can scale more quickly, reach more patients and avoid many of the access delays that have dogged autologous CAR-T products.On top of that, azer-cel already enjoys FDA Fast-Track status for relapsed/refractory DLBCL, giving Imugene extra regulatory velocity—so a more permissive commercial environment only magnifies its upside.
IMU Price at posting:
1.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)